Previous 10 | Next 10 |
2023-05-15 10:34:32 ET Akero Therapeutics press release ( NASDAQ: AKRO ): Q1 GAAP EPS of -$0.55. Akero's cash, cash equivalents and short-term marketable securities for the period ended March 31, 2023 were $343.2 million. For further details see: Akero Therapeuti...
-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 -- -- SYNCHRONY Phase 3 studies on track to begin enrolling in the second half ...
2023-05-09 04:37:35 ET Summary Akero Therapeutics has a proof of concept in using EFX for the treatment of patients with NASH Fibrosis established in the phase 2b HARMONY study. Results from cohort D of phase 2b SYMMETRY study using EFX on top of existing GLP-1 receptor agonist th...
2023-05-07 10:05:43 ET Summary AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY. However, SYMMETRY will prove its cirrhosis activity, so there may we...
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
2023-03-29 23:40:24 ET Summary NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million i...
2023-03-29 16:38:00 ET Akero Therapeutics said it had a positive end-of-Phase 2 meeting with the U.S. Food and Drug Administration and also discussed details of the upcoming Phase 3 trial of efruxifermin to treat nonalcoholic steatohepatitis ( NASH ). The company will start en...
The planned Phase 3 program consists of three trials, SYNCHRONY Histology , SYNCHRONY Real-World , and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH SYNCHRONY Histology and SYNCHRONY ...
2023-03-22 08:13:28 ET Luminar Technologies ( LAZR ) -9% . Petco Health and Wellness ( WOOF ) -9% on Q4 earnings release . Akero Therapeutics ( AKRO ) -8% . Dermata Therapeutics ( DRMA ) -7% . Qualigen Therapeutics ( QLGN ) -7%...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...